11.21
+0.13(+1.17%)
Currency In USD
| Previous Close | 11.08 |
| Open | 11.13 |
| Day High | 11.8 |
| Day Low | 11.02 |
| 52-Week High | 52.32 |
| 52-Week Low | 5.49 |
| Volume | 186,441 |
| Average Volume | 275,401 |
| Market Cap | 419.71M |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 10.97 |
| Moving Average 200 Days | 16.54 |
| Change | 0.13 |
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 21, 2025 11:00 AM GMT
MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases incl
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
GlobeNewswire Inc.
May 20, 2025 8:01 PM GMT
Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
GlobeNewswire Inc.
Apr 29, 2025 11:00 AM GMT
MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases in